Original Research
Published on 09 Jun 2023
Efficacy and safety of programmed cell death receptor 1 inhibition-based regimens in patients with pediatric malignancies: the real-world study in China
in Cancer Immunity and Immunotherapy
- 2,765 views
- 2 citations